Insight Molecular Diagnostics (IMDX) Accumulated Expenses (2016 - 2026)
Insight Molecular Diagnostics' Accumulated Expenses history spans 7 years, with the latest figure at $2.5 million for Q4 2025.
- On a quarterly basis, Accumulated Expenses rose 120.52% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 120.52% increase, with the full-year FY2025 number at $2.5 million, up 120.52% from a year prior.
- Accumulated Expenses hit $2.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $2.2 million in the prior quarter.
- Over the last five years, Accumulated Expenses for IMDX hit a ceiling of $4.1 million in Q3 2022 and a floor of $1.1 million in Q4 2023.
- Historically, Accumulated Expenses has averaged $2.1 million across 5 years, with a median of $2.0 million in 2022.
- Biggest five-year swings in Accumulated Expenses: skyrocketed 138.29% in 2021 and later crashed 57.66% in 2023.
- Tracing IMDX's Accumulated Expenses over 5 years: stood at $2.8 million in 2021, then crashed by 37.35% to $1.8 million in 2022, then tumbled by 36.98% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024, then soared by 120.52% to $2.5 million in 2025.
- Business Quant data shows Accumulated Expenses for IMDX at $2.5 million in Q4 2025, $2.2 million in Q3 2025, and $1.5 million in Q2 2025.